用camrelizumab与apatinib结合治疗的晚期胰腺癌:一个病例报告
Yun-Hao Luo1, Ting He2, Lu Lin3
1Department of Critical Care Medicine, Chengdu First People's Hospital, Chengdu 610000, Sichuan Province, China.
World journal of gastrointestinal oncology
|February 17, 2025
概括
免疫疗法和向疗法对胰腺癌 (PC) 患者有希望,这些患者对化疗反应不佳. 这项案例研究强调了改善生活质量和生存率,但需要进一步的试验.
科学领域:
- 在瘤学瘤学.
- 医学案例研究 医学案例研究
- 癌症研究 癌症研究
背景情况:
- 胰腺癌 (PC) 的5年生存率很低 (4%-12%),手术适用性有限 (15%-20%).
- 化疗对PC的疗效有限,PC容易复发和转移.
- 现有的治疗方法往往难以控制晚期胰腺癌的进展.
研究的目的:
- 报告胰腺癌病例,使用免疫疗法和向疗法.
- 评估新型治疗组合对患者结果的疗效和影响.
- 探索抗化疗胰腺癌的潜在新治疗途径.
主要方法:
- 对患有差分化胰腺癌的患者进行了组织病理学分析.
- 进行了连续的化疗方案,肝转移切除和放射治疗.
- 治疗方法被修改为包括用修改后的FOLFIRINOX,然后用camrelizumab和apatinib (向治疗) 的camrelizumab (免疫疗法).
主要成果:
- 坎雷利祖马布和阿帕蒂尼布联合治疗实现了瘤控制,减少住院时间,改善生活质量.
- 患者经历了免疫疗法和向治疗的长期无进展生存.
- 停止治疗导致迅速复发和转移,导致两个月内死亡.
结论:
- 免疫疗法和向疗法对胰腺癌患者具有潜在的益处,这些患者对化疗不耐药.
- 这些新型疗法可以改善选择PC患者的生活质量和生存时间.
- 进一步的临床试验至关重要,以确认免疫疗法和向治疗在胰腺癌中的疗效.
更多相关视频
12:07Laparoscopic Radical Antegrade Modular Pancreatosplenectomy via Dorsal-Caudal Artery Approach for Pancreatic Neck-Body Cancer
Published on: November 18, 2022
3.6K
07:08Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
707
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...